Pharmaceutical industries urged to ensure high quality of medicine
Wednesday, 16 June 2010
Health and Family Welfare Minister Dr AFM Ruhal Haque Tuesday appreciated the progress of local pharmaceutical industries, but urged the companies to ensure high quality of medicine for both local and international consumptions, reports BSS.
"Its a matter of great happiness that the local pharmaceutical companies have been meeting 97 per cent of domestic demands for medicine, but the quality of such drugs must be ensured," he said at a scientific seminar on 'Osteoporosis' at a city hotel.
Osteoporosis, a disease of hip, waist and spine, caused by abnormal loss of bony tissues that results in fragile porous bones owing to lack of calcium.
During osteoporosis the bone mineral density (BMD) is reduced, bone microarchitecture is disrupted, and the amount and variety of proteins in bone is altered.
The disease, mostly common in postmenopausal women, leads to an increased risk of bone fracture. Ruhal Haque, also a noted orthopedic surgeon, said steps have been taken to ensure marketing of quality drugs in the country. He said the drug administration has been upgraded along with provisions for new staff.
Besides, steps have also been taken to set up an active pharmaceutical ingredient (API) park in the outskirts of the capital city to ensure smooth supply of raw materials for medicine production.
An international standard drug testing laboratory would also be set up soon in the country to control quality of drugs produced in Bangladesh, he added.
The minister said the government has not only focussed on quality control of locally produced drugs, but also has taken steps to check pilferage and malpractice of drug procurement and distribution in public hospitals.
Managing Director of Incepta Pharmaceuticals Ltd Golam Muktadir also spoke on the occasion, where his company announced the inception of a new injection to prevent the disease.
The company said at least half of the osteoporosis patients increase their risk of bone fracture and deaths as they do not complete their treatment.
"Its a matter of great happiness that the local pharmaceutical companies have been meeting 97 per cent of domestic demands for medicine, but the quality of such drugs must be ensured," he said at a scientific seminar on 'Osteoporosis' at a city hotel.
Osteoporosis, a disease of hip, waist and spine, caused by abnormal loss of bony tissues that results in fragile porous bones owing to lack of calcium.
During osteoporosis the bone mineral density (BMD) is reduced, bone microarchitecture is disrupted, and the amount and variety of proteins in bone is altered.
The disease, mostly common in postmenopausal women, leads to an increased risk of bone fracture. Ruhal Haque, also a noted orthopedic surgeon, said steps have been taken to ensure marketing of quality drugs in the country. He said the drug administration has been upgraded along with provisions for new staff.
Besides, steps have also been taken to set up an active pharmaceutical ingredient (API) park in the outskirts of the capital city to ensure smooth supply of raw materials for medicine production.
An international standard drug testing laboratory would also be set up soon in the country to control quality of drugs produced in Bangladesh, he added.
The minister said the government has not only focussed on quality control of locally produced drugs, but also has taken steps to check pilferage and malpractice of drug procurement and distribution in public hospitals.
Managing Director of Incepta Pharmaceuticals Ltd Golam Muktadir also spoke on the occasion, where his company announced the inception of a new injection to prevent the disease.
The company said at least half of the osteoporosis patients increase their risk of bone fracture and deaths as they do not complete their treatment.